Don't be caught off-guard: Theravance Biopharma TBPH releases its next round of earnings Tuesday.
Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.
Earnings and Revenue
Wall Street expects an earnings loss of $1.17 per share and sales around $4.84 million.
Theravance Biopharma EPS in the same period a year ago came in at a loss of $1.36 per share and sales were $5 million. Analysts estimate would represent a 13.97 percent decrease in the company's earnings. Sales would be down 14.97 percent from the year-ago period.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | -1.2 | -1.14 | -1.14 | -1.05 |
EPS Actual | -1.12 | -1.27 | -1.27 | -1.36 |
Stock Performance
Over the last 52-week period, shares are down 7.54 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts' have adjusted their estimates higher for EPS and revenues over the past 90 days. The popular rating by analysts on Theravance Biopharma stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Theravance's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.